AUTHORS
Cinzia Pellegrini, MD, PhD, Marianna Gentilini, PhD2, Beatrice Casadei, MD, PhD3, Nicole Fabbri, MD4, Lisa Argnani5, Alessandro Broccoli, MD6, Simona Citro, MD7, Gianmarco Bagnato, MD8, Simone Rossello, MS9, Luca Castagna10, Silvia Gambara, MD11, Federica Cocito, MD12, Elisa Lucchini, MD13, Elena Sabattini14, Claudio Agostinelli15, Francesca Bonifazi16, Pier Luigi Zinzani, MD, PhD17
AFFILIATIONS
1 IRCCS Azieda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, BO, Italy
2 Department of Medical and Surgical sciences DIMEC, University of Bologna, Bologna, Italy
3 IRCCS Azieda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, BO, Italy
4 Department of Medical and Surgical sciences DIMEC, University of Bologna, Bologna, Italy
5 Department of Medical and Surgical sciences DIMEC, University of Bologna, Bologna, Italy
6 Department of Medical and Surgical sciences DIMEC, University of Bologna, Bologna, Italy
7 Department of Medical and Surgical sciences DIMEC, University of Bologna, Bologna, Italy
8 Department of Medical and Surgical sciences DIMEC, University of Bologna, Bologna, Italy
9 Department of Medical and Surgical sciences DIMEC, University of Bologna, Bologna, Italy
10 BMT Unit, AOR Villa Sofia Cervello, Palermo, Italy
11 Azienda USL IRCCS of Reggio Emilia, Reggio Emilia, Italy
12 Hematology Unit Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
13 UCO Ematologia Azienda Sanitaria Universitaria Giuliano Isontina, Ospedale Maggiore, Trieste, Italy
14 Unità di Emolinfopatologia IRCSS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
15 Unità di Emolinfopatologia IRCSS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
16 IRCCS Azieda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, BO, Italy
17 Department of Medical and Surgical sciences DIMEC, University of Bologna, Bologna, Italy, IRCCS Azieda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, BO, Italy
ABSTRACT
Peripheral T-cell lymphomas (PTCL) are rare and aggressive malignancies with poor outcomes, particularly in relapsed/refractory (r/r) setting, where therapeutic options remain limited and enrollment in clinical trials is strongly recommended. For transplant-eligible patients, long-term disease control and potential cure largely rely on achieving disease response with salvage therapy followed by consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Valemetostat tosylate, a first-in-class dual EZH1/2 inhibitor, is approved in Japan for r/r adult T-cell leukemia/lymphoma based on a phase 2 study reporting an objective response rate (ORR) of 44%, with promising activity observed in r/r PTCL. Since valemetostat has not been approved outside Japan, real-world evidence remains scarce. To our knowledge, this multicenter Italian cohort represents the first reported real-world experience. We retrospectively analyzed consecutive adult patients with r/r PTCL who received at least one cycle of valemetostat between January 2025 and March 2026 across 4 Italian centers. Diagnoses were rendered according to the World Health Organization Classification 2022 and the International Consensus Classification. Valemetostat was provided through the Italian AIFA 5% Fund and administered orally at 200 mg once daily. Baseline demographic, clinical, and disease characteristics were collected. Response was assessed according to Lugano criteria. PET/CT was performed after 2 cycles (interim assessment), after cycles 5 and 13, and at end of treatment. CT scans were scheduled every 8 weeks during cycles 1-7, every 12 weeks during cycles 8-40, and every 6 cycles thereafter. Adverse events were graded according to CTCAE v5.0. The primary endpoints were ORR and complete remission rate (CR). Secondary endpoints included survivals and duration of response (DOR), safety, treatment duration, and the feasibility of subsequent allo-HSCT. We identify 12 patients with r/r PTCL treated with valemetostat and evaluable for response. Histologic subtypes included: nodal T-follicular helper (TFH) lymphoma, NOS (n=6, 50%), nodal TFH lymphoma, angioimmunoblastic type (n=3, 25%), and PTCL-NOS (n=3, 25%). Baseline characteristics at valemetostat initiation were as follows: median age 54 years (range, 30-75), 58% male, 92% stage III-IV disease, 58% with B symptoms and 50% with extranodal involvement. Baseline mPIT scores were low in 3 patients (25%), low-intermediate in 5 (42%), and high-intermediate in 2 (17%). Patients had received a median of 2 prior lines of therapy (range, 1-5), and 92% were refractory to their most recent treatment. Initial regimens were as follows: CHOP/CHOEP (n=9), COMP (n=2), GDP (1). In the relapse setting 41% of patient received brentuximab vedotin and 25% received investigational agents within clinical trials. No patient had previously undergone autologous stem cell transplantation. At data cutoff, patients had received a median of 6 cycles of valemetostat (range, 1-12), and three patients remained on treatment. The best ORR was 67%, including 2 CR (17%) and 6 partial responses (50%). Notably, both CRs were achieved at the first scheduled PET/CT assessment after 2 cycles. Following valemetostat-induced disease control, 4 patients successfully proceeded to allo-HSCT, and 3remain in ongoing remission at last follow-up. DOR is 6.3 months (range 2.3-12.1). Treatment was generally well tolerated. Grade ≥3 hematologic adverse events included anemia requiring red blood cell transfusion (n=1), thrombocytopenia requiring platelet transfusions (n=1), and grade 4 neutropenia requiring G-CSF support (n=2). Infectious adverse events were reported in 6 patients (50%), including 2 serious adverse events requiring hospitalization (bacterial pneumonia and CMV pneumonia), 5 bacterial infections, 1 rhinovirus infection, and 1 pulmonary aspergillosis. All infectious complications resolved with appropriate treatment. In this first Italian real-world experience, valemetostat confirmed its promising clinical activity and manageable safety profile in heavily pretreated patients with r/r PTCL. Rapid and durable responses were observed, and disease control achieved with valemetostat enabled subsequent allo-HSCT in a subset of patients. These findings support valemetostat as a valuable therapeutic option and potential bridge to transplantation in a setting with limited treatment alternatives.
DISCLOSURES
Cinzia Pellegrini, MD, PhD: Pierre Fabre - Consultancy (Includes expert testimony); Be-One - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony)